Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition

Immunophenotyping of Newly Diagnosed and Recurrent Glioblastoma Defines Distinct Immune Exhaustion Profiles in Peripheral and Tumor-infiltrating Lymphocytes

(2018) Malte Mohme et al.   CLINICAL CANCER RESEARCH

T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma

(2018) Karolina Woroniecka et al.   CLINICAL CANCER RESEARCH

Temozolomide for immunomodulation in the treatment of glioblastoma

(2018) Aida Karachi et al.   NEURO-ONCOLOGY

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma

(2018) Carter M. Suryadevara et al.   OncoImmunology

Serial changes in lymphocyte subsets in patients with newly diagnosed high grade astrocytomas treated with standard radiation and temozolomide

(2017) Jian L. Campian et al.   JOURNAL OF NEURO-ONCOLOGY

Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma

(2017) Maria-Carmela Speranza et al.   NEURO-ONCOLOGY

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

Expression differences of programmed death ligand 1 in de-novo and recurrent glioblastoma multiforme

(2017) Sabrina Heynckes et al.   Oncotarget

Recurrent glioma clinical trial, CheckMate-143: the game is not over yet

(2017) Anna C. Filley et al.   Oncotarget

Immune targets and neoantigens for cancer immunotherapy and precision medicine

(2016) Rong-Fu Wang et al.   CELL RESEARCH

Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas

(2016) Jennifer E. Kim et al.   CLINICAL CANCER RESEARCH

Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy

(2016) Christina Pfirschke et al.   IMMUNITY

Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency

(2016) Eric Bouffet et al.   JOURNAL OF CLINICAL ONCOLOGY

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

(2016) N. McGranahan et al.   SCIENCE

Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM

(2016) D. Mathios et al.   Science Translational Medicine

Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy

(2016) T. M. Johanns et al.   Cancer Discovery

Pre-radiation lymphocyte harvesting and post-radiation reinfusion in patients with newly diagnosed high grade gliomas

(2015) Jian L. Campian et al.   JOURNAL OF NEURO-ONCOLOGY

Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients

(2015) Duane A. Mitchell et al.   NATURE

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model

(2015) D. A. Reardon et al.   Cancer Immunology Research

Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas

(2015) Catherine Flores et al.   OncoImmunology

Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models

(2014) M. Candolfi et al.   CLINICAL CANCER RESEARCH

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Intratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion

(2013) Sara Fritzell et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide

(2013) Luis Sanchez-Perez et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas

(2013) Jing Zeng et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients

(2013) Laura Ridolfi et al.   Journal of Translational Medicine

Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models

(2013) Ling Cen et al.   NEURO-ONCOLOGY

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Myeloablative Temozolomide Enhances CD8+ T-Cell Responses to Vaccine and Is Required for Efficacy against Brain Tumors in Mice

(2013) Luis A. Sanchez-Perez et al.   PLoS One

Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma

(2013) B. E. Johnson et al.   SCIENCE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters

(2012) Guangchuang Yu et al.   OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY

Monoclonal antibody blockade of IL-2 receptor   during lymphopenia selectively depletes regulatory T cells in mice and humans

(2011) D. A. Mitchell et al.   BLOOD

ggplot2: Elegant Graphics for Data Analysis

(2011) Cedric Ginestet   JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES A-STATISTICS IN SOCIETY

Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma

(2011) D.-S. Kong et al.   NEURO-ONCOLOGY

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma

(2010) J. H. Sampson et al.   NEURO-ONCOLOGY

Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model

(2009) Claire Banissi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance

(2009) S. Yip et al.   CLINICAL CANCER RESEARCH

Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma

(2009) Jennifer L. Clarke et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

(2009) Loise M. Francisco et al.   JOURNAL OF EXPERIMENTAL MEDICINE